Acta Pol Pharm
-
Comparative Study
The effect of gabapentin on antinociceptive action of analgesics.
The effect of gabapentin at a dose of 10 mg/kg (single administration) and at 3 mg/kg/day (administered for 10 days) on the analgesic action of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg and 1.4 mg/kg) in mice was assessed on the basis of hot-plate and tail-flick tests. All the drugs were administered intraperitoneally (i.p.). Gabapentin was administered to mice 30 min before the administration of analgesics. ⋯ The single dose of gabapentin enhances the analgesic effect of morphine in the hot-plate test, whereas in the tail-flick test it demonstrates an opposite effect. Gabapentin in a single dose does not affect significantly the effects of metamizol and indomethacin, whereas multiple doses decrease the action of these drugs. Gabapentin abolishes the tolerance of antinociceptive effect of morphine.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Osteolytic bone destruction, caused by the aberrant production and activation of osteoclasts, results in significant morbidity for patients with multiple myeloma (MM). Pamidronate [(3-amino-1-hydroxypropylidene)-1,1-bis-phosphonate] inhibits osteoclastic activity and reduces bone resorption. A potency of zoledronic acid (2-[imidazol-1-yl]-1-hydroxyethylidene-1,1-bisphosphonic acid, a new third generation bisphosphonate, as inhibitor of resorption was 850-fold greater than pamidronate, as was shown in preclinical models of bone resorption. ⋯ At present actual median survival time of analysed patients since MM diagnosis is 42 months, since the beginning of treatment with pamidronate and zoledronic acid--33 months, and since completing treatment--20 months and is similar in 3 treatment groups. As was shown in our single center study in MM patients the safety and efficacy of pamidronate 90 mg and zoledronic acid 4 mg and 8 mg in monthly i.v. infusion are comparable. Thus the recommended dosage of zoledronic acid is 4 mg administered as a 15 minute i.v. infusion at intervals of 3 to 4 weeks.
-
Propanidid and etomidate were extracted from blood with diethyl ether at pH ca. 8 (phosphate buffer), then separated and identified by thin-layer chromatography on silica gel, using diethyl ether-acetone (3:1, v/v) for propanidid or dioxane-acetic acid (47:3, v/v) for etomidate as the mobile phase. Both compounds can be revealed on dried chromatograms using sodium carbonate solution up to the amount 1 microg/cm3 of plasma, and it is sufficient sensivity for propanidid adhibited in therapeutic doses, whereas this limits the detection of etomidate for overdosed patients only.
-
High-performance reversed-phase liquid chromatographic determination of propanidid and etomidate was performed on ODS silica, after precipitation of the proteins in plasma with methanol, extraction of the drugs with diethyl ether, evaporation and dissolving in a mobile phase: acetonitrile-phosphate buffer pH 4.44 (7:3, v/v); UV detection at 254 nm. Dionine hydrochloride was used as an internal standard. Propanidid was determined in a range 5-25 microg/cm3 of plasma and etomidate in 0.1-0.5 microg/cm3 of plasma, thus enables the analysis of therapeutic levels of the drugs.